Accenture ( ACN) initiated at Morgan Stanley: Morgan Stanley initiates coverage of Accenture with an overweight rating and a $44 price target. Chicago Merc ( CME) upgraded at Prudential: CME was upgraded from Underweight to Neutral at Prudential. $570 price target. Estimates also raised, as volume growth has not slowed down as much as expected. Diamond Offshore ( DO) upgraded at Credit Suisse: Credit Suisse is upgrading DO to Outperform from Neutral based on valuation. Raises target price to $101 from $93. Investors Financial ( IFIN) downgraded at Prudential: IFIN was downgraded from Neutral to Underweight at Prudential. $38 price target. U.S. growth has slowed considerably, while expenses continue to rise. Intuit ( INTU) upgraded at JP Morgan: INTU was upgraded to Overweight at JP Morgan. Expect the company to have a strong tax season, and post solid QuickBooks sales. Juniper Networks ( JNPR) downgraded at Thomas Weisel: Thomas Weisel downgrades Juniper Networks to market weight on increasingly balanced risk/reward equation. Motorola ( MOT) downgraded at Morgan Stanley: Morgan Stanley downgrades Motorola from overweight to equalweight and cuts 2007-08 eps estimates. Nasdaq ( NDAQ) downgraded at Morgan Stanley: Morgan Stanley downgrades Nasdaq Stock Market from overweight to equalweight and lowers its price target from $39 to $36. Pfizer ( PFE) downgraded at Bear: PFE was downgraded from Outperform to Peer Perform at Bear Stearns. Lipitor volumes are decelerating, and there are few big products in the near-term pipeline. Parexel ( PRXL) upgraded at Goldman Sachs: Goldman is upgrading PRXL to Buy from Neutral based on valuation. Believe company can show further fundamental improvement in strong market for clinical services. Target price at $38. Patni ( PTI) upgraded at Goldman Sachs: Goldman is upgrading PTI to Neutral from Sell based on sustained secular demand and growth for offshore services, as well as increased estimates for 20% revenue growth in 2007 and 2008. Believe earnings downside is limited due to higher revenue growth rate. Price target raised to $18.40 from $15.16. Robert Half ( RHI) upgraded at UBS: RHI upgraded to Buy rating from Neutral at UBS. Price target jumps to $53 from $40. 2007 eps estimates rise to $2.00 from $1.92.